Your trusted source for investing success

Tag: therapeutics

FREE Report - How Will Trump Affect Your Gold Investments? 

Trump’s policies are affecting gold. You should know what’s going on. Click here to get our FREE report.

Click here to get your free report!

Discover what the experts see coming in the Age of Trump with our INN Insider's Report free of charge! Includes expert insights into Trump and his effect on mining and gold.

 
Licensed Producers Are Going Global, But This One Stands Out

Licensed Producers Are Going Global, But This One Stands Out

CFN Media Group (“CannabisFN”), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering Harvest One Cannabis Inc.(TSXV:HVST) tremendous progress in growing its international footprint. The company’s wholly-owned United Greeneries subsidiary is awaiting approval from Health Canada for its ACMPR license to sell, but its

Revive Therapeutics Announces Positive Results of its Novel Cannabinoid Delivery Technology

Revive Therapeutics (TSXV:RVV; OTCQB:RVVTF) has announced positive initial results from its research product with the University of Wisconsin-Madison for the development of a novel cannabinoid delivery technology.

As quoted in the press release:
The research project evaluated tannin-chitosan (TNN-CHT) based hydrogel formulations in combination with synthetic cannabidiol (CBD) in an anti-inflammatory preclinical

PacBio and Bluebee Launch De Novo Genome Assembly Pipeline on the Bluebee Analysis Platform

Bluebee, a company driving genomic data-driven medicine, and Pacific Biosciences of California, Inc. (NASDAQ: PACB), the leader in long-read sequencing, announced they have integrated the PacBio® de novo assembly pipeline onto the Bluebee® genomics analysis platform. The integration creates a simplified workflow and fully automated, end-to-end data analysis solution that allows

Emblem Announces Exclusive Agreement with Canntab Therapeutics for Cannabinoid Based Oral Sustained Release Formulation

Emblem Announces Exclusive Agreement with Canntab Therapeutics for Cannabinoid Based Oral Sustained Release Formulation

Emblem Corp. (TSXV:EMC) (EMC.WT) (“Emblem” or the “Company”) announced today that it has entered into a Collaboration and Licensing Agreement (the “Agreement”) with Canntab Therapeutics Limited (“Canntab”) of Toronto. Canntab has developed a patent-pending oral sustained release formulation for cannabinoids (the “Sustained Release Product” or the “Product”). Under the Agreement,

Harvest One provides Update on subsidiary Satipharm and Sales License

Harvest One provides Update on subsidiary Satipharm and Sales License

Harvest One Cannabis Inc.(TSXV:HVST)  is pleased to provide a market update on its wholly owned subsidiary, Satipharm AG (“Satipharm”):

Satipharm has received German “Free Sales Certificate” reducing constraints for international export
Australian Regulatory Authority has issued final approval for CBD capsule prescription in Australia
Strong increase in European dietary supplement

Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
22nd Century Group Shares Production Update

URL: https://investingnews.com/daily/resource-investing/agriculture-investing/cannabis-investing/22nd-century-group-shares-production-update/